{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:40:23Z","timestamp":1793706023957,"version":"4.6.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01858-x","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T14:46:59Z","timestamp":1756651619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Integrating multi-omics approaches in acute myeloid leukemia (AML): Advancements and clinical implications"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"issue":"12","key":"1858_CR1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"1","key":"1858_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"23","key":"1858_CR3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"1858_CR4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10238-025-01783-z","volume":"25","author":"M Abdar Esfahani","year":"2025","unstructured":"Abdar Esfahani M, et al. The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations. Clin Exp Med. 2025;25(1):230.","journal-title":"Clin Exp Med"},{"issue":"7728","key":"1858_CR5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526\u201331.","journal-title":"Nature"},{"issue":"3","key":"1858_CR6","first-page":"28","volume":"11","author":"A Noroozi Aghide","year":"2016","unstructured":"Noroozi Aghide A, Soleimani Samarkhazan H, Ahmadnezhad M. Effect of harmine alkaloid on the expression of P16 and DAPK in HL60 leukemia cell line. Paramed Sci Mil Health. 2016;11(3):28\u201333.","journal-title":"Paramed Sci Mil Health"},{"issue":"1","key":"1858_CR7","volume":"7","author":"QT Trac","year":"2023","unstructured":"Trac QT, et al. Prediction model for drug response of acute myeloid leukemia patients. NPJ Precis Oncol. 2023;7(1):32.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"1858_CR8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176(6):1265-1281.e24.","journal-title":"Cell"},{"issue":"1","key":"1858_CR9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13059-020-02015-1","volume":"21","author":"R Argelaguet","year":"2020","unstructured":"Argelaguet R, et al. MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data. Genome Biol. 2020;21(1):111.","journal-title":"Genome Biol"},{"issue":"7","key":"1858_CR10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nm.4125","volume":"22","author":"S Li","year":"2016","unstructured":"Li S, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016;22(7):792\u20139.","journal-title":"Nat Med"},{"issue":"10","key":"1858_CR11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2022018092","volume":"141","author":"SK Mishra","year":"2023","unstructured":"Mishra SK, Millman SE, Zhang L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. 2023;141(10):1119\u201335.","journal-title":"Blood"},{"issue":"2","key":"1858_CR12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth C, et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 2022;12(2):372\u201387.","journal-title":"Cancer Discov"},{"key":"1858_CR13","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.764698","volume":"9","author":"DB Pimenta","year":"2021","unstructured":"Pimenta DB, et al. The bone marrow microenvironment mechanisms in acute myeloid leukemia. Front Cell Dev Biol. 2021;9:764698.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"1858_CR14","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000896","volume":"7","author":"C Tomasoni","year":"2023","unstructured":"Tomasoni C, et al. A question of frame: the role of the bone marrow stromal niche in myeloid malignancies. Hemasphere. 2023;7(6):e896.","journal-title":"Hemasphere"},{"issue":"1","key":"1858_CR15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11033-025-10692-z","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Curcumin and acute myeloid leukemia: a golden hope, updated insights. Mol Biol Rep. 2025;52(1):583.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"1858_CR16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536\u201351.","journal-title":"Cancer Discov"},{"issue":"1","key":"1858_CR17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s42003-020-01334-0","volume":"3","author":"YF Pei","year":"2020","unstructured":"Pei YF, et al. The genetic architecture of appendicular lean mass characterized by association analysis in the UK Biobank study. Commun Biol. 2020;3(1):608.","journal-title":"Commun Biol"},{"issue":"12","key":"1858_CR18","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859\u201366.","journal-title":"Nat Med"},{"issue":"3","key":"1858_CR19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/jha2.466","volume":"3","author":"DDH Kim","year":"2022","unstructured":"Kim DDH, et al. The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. EJHaem. 2022;3(3):873\u201384.","journal-title":"EJHaem"},{"issue":"7633","key":"1858_CR20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433\u20137.","journal-title":"Nature"},{"issue":"6","key":"1858_CR21","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","volume":"30","author":"AJ Widman","year":"2024","unstructured":"Widman AJ, et al. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nat Med. 2024;30(6):1655\u201366.","journal-title":"Nat Med"},{"issue":"7954","key":"1858_CR22","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u20134.","journal-title":"Nature"},{"key":"1858_CR23","doi-asserted-by":"crossref","unstructured":"Danek, B., et al., Federated Learning for multi-omics: a performance evaluation in Parkinson\u2019s disease. bioRxiv, 2024.","DOI":"10.1101\/2023.10.04.560604"},{"issue":"1","key":"1858_CR24","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita K, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11(1):5327.","journal-title":"Nat Commun"},{"issue":"12","key":"1858_CR25","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1038\/s41375-024-02423-3","volume":"38","author":"Z Li","year":"2024","unstructured":"Li Z, et al. Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells. Leukemia. 2024;38(12):2699\u2013708.","journal-title":"Leukemia"},{"issue":"22","key":"1858_CR26","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"8","key":"1858_CR27","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35846","volume":"131","author":"MR Khouri","year":"2025","unstructured":"Khouri MR, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. 2025;131(8):e35846.","journal-title":"Cancer"},{"issue":"3","key":"1858_CR28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41375-022-01796-7","volume":"37","author":"S Stratmann","year":"2023","unstructured":"Stratmann S, et al. Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. Leukemia. 2023;37(3):550\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"1858_CR29","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100517","volume":"22","author":"P Casado","year":"2023","unstructured":"Casado P, Cutillas PR. Proteomic characterization of acute myeloid leukemia for precision medicine. Mol Cell Proteomics. 2023;22(4):100517.","journal-title":"Mol Cell Proteomics"},{"issue":"10","key":"1858_CR30","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein JN, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113\u201320.","journal-title":"Nat Genet"},{"issue":"1","key":"1858_CR31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10238-025-01724-w","volume":"25","author":"A Bayani","year":"2025","unstructured":"Bayani A, et al. Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy. Clin Exp Med. 2025;25(1):186.","journal-title":"Clin Exp Med"},{"issue":"6","key":"1858_CR32","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AG Zeng","year":"2022","unstructured":"Zeng AG, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat med. 2022;28(6):1212\u201323.","journal-title":"Nat med"},{"issue":"321","key":"1858_CR33","first-page":"ra36","volume":"7","author":"AK Eisfeld","year":"2014","unstructured":"Eisfeld AK, et al. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. Sci Signal. 2014;7(321):ra36.","journal-title":"Sci Signal"},{"issue":"10","key":"1858_CR34","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1038\/bcj.2015.76","volume":"5","author":"M D\u00edaz-Bey\u00e1","year":"2015","unstructured":"D\u00edaz-Bey\u00e1 M, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J. 2015;5(10):e352.","journal-title":"Blood Cancer J"},{"issue":"25","key":"1858_CR35","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood.2024027244","volume":"145","author":"PK Reville","year":"2025","unstructured":"Reville PK, et al. Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes. Blood. 2025;145(25):3015\u201329.","journal-title":"Blood"},{"key":"1858_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06387-x","author":"OS Aval","year":"2025","unstructured":"Aval OS, et al. Galectin-9: a double-edged sword in acute myeloid leukemia. Ann Hematol. 2025. https:\/\/doi.org\/10.1007\/s00277-025-06387-x.","journal-title":"Ann Hematol"},{"issue":"23","key":"1858_CR37","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1158\/1078-0432.CCR-23-0917","volume":"29","author":"LN Harris","year":"2023","unstructured":"Harris LN, et al. The new NCI precision medicine trials. Clin Cancer Res. 2023;29(23):4728\u201332.","journal-title":"Clin Cancer Res"},{"key":"1858_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071967","author":"IW Song","year":"2023","unstructured":"Song IW, et al. Precision oncology: evolving clinical trials across tumor types. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15071967.","journal-title":"Cancers (Basel)"},{"issue":"42","key":"1858_CR39","doi-asserted-by":"crossref","first-page":"26711","DOI":"10.18632\/oncotarget.25475","volume":"9","author":"JK Lamba","year":"2018","unstructured":"Lamba JK, et al. Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. Oncotarget. 2018;9(42):26711\u201323.","journal-title":"Oncotarget"},{"issue":"Supplement 1","key":"1858_CR40","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2023-180336","volume":"142","author":"Y Ochi","year":"2023","unstructured":"Ochi Y, et al. Epigenetic classification of acute myeloid leukemia revealed by genome-wide chromatin profiling. Blood. 2023;142(Supplement 1):836\u2013836.","journal-title":"Blood"},{"issue":"7","key":"1858_CR41","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, et al. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873\u201389.","journal-title":"Leukemia"},{"issue":"1","key":"1858_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11899-017-0363-4","volume":"12","author":"C Gardin","year":"2017","unstructured":"Gardin C, Dombret H. Hypomethylating agents as a therapy for AML. Curr Hematol Malig Rep. 2017;12(1):1\u201310.","journal-title":"Curr Hematol Malig Rep"},{"key":"1858_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070641","author":"VG Sorrentino","year":"2021","unstructured":"Sorrentino VG, et al. Hypomethylating chemotherapeutic agents as therapy for myelodysplastic syndromes and prevention of acute myeloid leukemia. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14070641.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1858_CR44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, et al. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13(1):73.","journal-title":"Biomark Res"},{"issue":"6","key":"1858_CR45","first-page":"699","volume":"133","author":"QY Xu","year":"2020","unstructured":"Xu QY, Yu L. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. Chin Med J Engl. 2020;133(6):699\u2013715.","journal-title":"Chin Med J Engl"},{"issue":"9","key":"1858_CR46","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70006","volume":"8","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, et al. Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A-rearranged acute leukemia. Hemasphere. 2024;8(9):e70006.","journal-title":"Hemasphere"},{"issue":"1","key":"1858_CR47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40364-024-00600-1","volume":"12","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, et al. Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia. Biomark Res. 2024;12(1):60.","journal-title":"Biomark Res"},{"key":"1858_CR48","doi-asserted-by":"crossref","unstructured":"Hu, C. and A.A. Qutub, Proteomics in Acute Myeloid Leukemia, in Myeloid Leukemia, A. Lasfar, Editor. 2017, IntechOpen: Rijeka.","DOI":"10.5772\/intechopen.70929"},{"issue":"1","key":"1858_CR49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11033-025-10527-x","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia. Mol Biol Rep. 2025;52(1):464.","journal-title":"Mol Biol Rep"},{"issue":"7","key":"1858_CR50","volume":"5","author":"DGJ Cucchi","year":"2021","unstructured":"Cucchi DGJ, et al. Phosphoproteomic characterization of primary AML samples and relevance for response toward FLT3-inhibitors. Hemasphere. 2021;5(7):e606.","journal-title":"Hemasphere"},{"issue":"6","key":"1858_CR51","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41375-020-01050-y","volume":"35","author":"HC Murray","year":"2021","unstructured":"Murray HC, et al. Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia. Leukemia. 2021;35(6):1782\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"1858_CR52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, et al. Targeting p53 pathways: mechanisms, structures and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92.","journal-title":"Signal Transduct Target Ther"},{"key":"1858_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194816","author":"DY Shin","year":"2023","unstructured":"Shin DY. TP53 mutation in acute myeloid leukemia: an old foe revisited. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15194816.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1858_CR54","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.2022019047","volume":"142","author":"BZ Carter","year":"2023","unstructured":"Carter BZ, et al. Epichaperome inhibition targets TP53-mutant AML and AML stem\/progenitor cells. Blood. 2023;142(12):1056\u201370.","journal-title":"Blood"},{"issue":"5","key":"1858_CR55","doi-asserted-by":"crossref","first-page":"R765","DOI":"10.1186\/bcr1290","volume":"7","author":"A Rehman","year":"2005","unstructured":"Rehman A, et al. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res. 2005;7(5):R765\u201374.","journal-title":"Breast Cancer Res"},{"key":"1858_CR56","doi-asserted-by":"crossref","unstructured":"Hurrish, K.H., et al., Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and\/or purine biosynthesis. Res Sq, 2023.","DOI":"10.1016\/j.bcp.2023.115981"},{"issue":"10","key":"1858_CR57","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1158\/2159-8290.CD-23-1145","volume":"14","author":"AI Sheth","year":"2024","unstructured":"Sheth AI, et al. Targeting acute myeloid leukemia stem cells through perturbation of mitochondrial calcium. Cancer Discov. 2024;14(10):1922\u201339.","journal-title":"Cancer Discov"},{"issue":"1","key":"1858_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","volume":"36","author":"L de Beauchamp","year":"2022","unstructured":"de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022;36(1):1\u201312.","journal-title":"Leukemia"},{"issue":"5","key":"1858_CR59","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","volume":"27","author":"CL Jones","year":"2020","unstructured":"Jones CL, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27(5):748-764.e4.","journal-title":"Cell Stem Cell"},{"key":"1858_CR60","volume":"18","author":"HA Tirado","year":"2023","unstructured":"Tirado HA, et al. Metabolic crosstalk between stromal and malignant cells in the bone marrow niche. Bone Rep. 2023;18:101669.","journal-title":"Bone Rep"},{"key":"1858_CR61","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.75908","author":"N Vilaplana-Lopera","year":"2022","unstructured":"Vilaplana-Lopera N, et al. Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells. Elife. 2022. https:\/\/doi.org\/10.7554\/eLife.75908.","journal-title":"Elife"},{"issue":"5","key":"1858_CR62","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3923\/ijp.2023.632.641","volume":"19","author":"Q Su","year":"2023","unstructured":"Su Q, et al. Dihydroartemisinin increases the sensitivity of acute myeloid leukemia cells to cytarabine via the Nrf2\/HO-1 anti-oxidant signaling pathway. IJP. 2023;19(5):632\u201341.","journal-title":"IJP"},{"issue":"1","key":"1858_CR63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41588-018-0270-1","volume":"51","author":"SA Assi","year":"2019","unstructured":"Assi SA, et al. Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nat Genet. 2019;51(1):151\u201362.","journal-title":"Nat Genet"},{"key":"1858_CR64","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108735","volume":"178","author":"\u0391 Kosvyra","year":"2024","unstructured":"Kosvyra \u0391, et al. Machine learning and integrative multi-omics network analysis for survival prediction in acute myeloid leukemia. Comput Biol Med. 2024;178:108735.","journal-title":"Comput Biol Med"},{"issue":"1","key":"1858_CR65","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1038\/s41467-025-58921-0","volume":"16","author":"G Zhang","year":"2025","unstructured":"Zhang G, et al. TRAPT: a multi-stage fused deep learning framework for predicting transcriptional regulators based on large-scale epigenomic data. Nat Commun. 2025;16(1):3611.","journal-title":"Nat Commun"},{"issue":"1","key":"1858_CR66","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1186\/s12967-025-06797-5","volume":"23","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. The microbiome in graft-versus-host disease: a tale of two ecosystems. J Transl Med. 2025;23(1):832.","journal-title":"J Transl Med"},{"issue":"12","key":"1858_CR67","doi-asserted-by":"crossref","DOI":"10.1002\/pon.70045","volume":"33","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Effects of web-based acceptance and commitment therapy on health-related outcomes among patients with lung cancer: a feasibility randomized controlled trial. Psychooncology. 2024;33(12):e70045.","journal-title":"Psychooncology"},{"key":"1858_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215364","author":"N Honor\u00e9","year":"2021","unstructured":"Honor\u00e9 N, et al. Liquid biopsy to detect minimal residual disease: methodology and impact. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13215364.","journal-title":"Cancers (Basel)"},{"key":"1858_CR69","unstructured":"Soleimani Samarkhazan, H., et al., Nanosensors in Leukemia Management: Pioneering Real-Time Biomarker Detection for Precision Oncology. Nano Select. n\/a(n\/a): p. e70039."},{"issue":"1","key":"1858_CR70","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK, et al. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Exp Med. 2025;25(1):166.","journal-title":"Clin Exp Med"},{"issue":"Supplement 1","key":"1858_CR71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2024-202802","volume":"144","author":"XX Lin","year":"2024","unstructured":"Lin XX, et al. Mapping the drug combination landscape for AML: an integrative ex vivo functional and computational approach. Blood. 2024;144(Supplement 1):271\u2013271.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1858_CR72","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/blood-2023-174114","volume":"142","author":"A Pandey","year":"2023","unstructured":"Pandey A, et al. The novel profiling relative inhibition simultaneously in mixtures (PRISM) platform identifies synergistic activity of lanraplenib and ruxolitinib in hematological malignancies. Blood. 2023;142(Supplement 1):2259\u20132259.","journal-title":"Blood"},{"key":"1858_CR73","volume":"144","author":"DY Sun","year":"2025","unstructured":"Sun DY, et al. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. Int Immunopharmacol. 2025;144:113392.","journal-title":"Int Immunopharmacol"},{"issue":"21","key":"1858_CR74","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","volume":"30","author":"P Desai","year":"2024","unstructured":"Desai P, et al. A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed\/refractory hematologic malignancies. Clin Cancer Res. 2024;30(21):4844\u201355.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1858_CR75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13059-023-03047-z","volume":"24","author":"Y Yu","year":"2023","unstructured":"Yu Y, et al. Correcting batch effects in large-scale multiomics studies using a reference-material-based ratio method. Genome Biol. 2023;24(1):201.","journal-title":"Genome Biol"},{"issue":"1","key":"1858_CR76","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13059-024-03401-9","volume":"25","author":"Y Yu","year":"2024","unstructured":"Yu Y, et al. Assessing and mitigating batch effects in large-scale omics studies. Genome Biol. 2024;25(1):254.","journal-title":"Genome Biol"},{"key":"1858_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad269","author":"Q Wang","year":"2023","unstructured":"Wang Q, et al. AFEI: adaptive optimized vertical federated learning for heterogeneous multi-omics data integration. Brief Bioinform. 2023. https:\/\/doi.org\/10.1093\/bib\/bbad269.","journal-title":"Brief Bioinform"},{"issue":"1","key":"1858_CR78","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1038\/s41467-022-30223-9","volume":"13","author":"MA Bassal","year":"2022","unstructured":"Bassal MA, et al. Germline mutations in mitochondrial complex i reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nat Commun. 2022;13(1):2614.","journal-title":"Nat Commun"},{"issue":"12","key":"1858_CR79","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/14789450.2024.2431272","volume":"21","author":"HC Murray","year":"2024","unstructured":"Murray HC, et al. Proteogenomic profiling of acute myeloid leukemia to identify therapeutic targets. Expert Rev Proteomics. 2024;21(12):515\u201328.","journal-title":"Expert Rev Proteomics"},{"issue":"1","key":"1858_CR80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","volume":"18","author":"Y Hasin","year":"2017","unstructured":"Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.","journal-title":"Genome Biol"},{"issue":"6","key":"1858_CR81","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.scib.2025.01.016","volume":"70","author":"Y Hu","year":"2025","unstructured":"Hu Y, et al. Enhancing panvascular medicine: unveiling the nexus of pan-cardio-oncology and expanding therapeutic frontiers. Sci Bull. 2025;70(6):798\u2013800.","journal-title":"Sci Bull"},{"issue":"10","key":"1858_CR82","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.cell.2021.03.050","volume":"184","author":"OM de Goede","year":"2021","unstructured":"de Goede OM, et al. Population-scale tissue transcriptomics maps long non-coding RNAs to complex disease. Cell. 2021;184(10):2633-2648.e19.","journal-title":"Cell"},{"key":"1858_CR83","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, et al. One stone, two birds: the roles of Tim-3 in acute myeloid leukemia. Front Immunol. 2021;12:618710.","journal-title":"Front Immunol"},{"issue":"6","key":"1858_CR84","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s12185-013-1433-6","volume":"98","author":"Y Kikushige","year":"2013","unstructured":"Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol. 2013;98(6):627\u201333.","journal-title":"Int J Hematol"},{"issue":"10","key":"1858_CR85","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-22-2433","volume":"83","author":"M Li","year":"2023","unstructured":"Li M, et al. LSD1 inhibition disrupts super-enhancer-driven oncogenic transcriptional programs in castration-resistant prostate cancer. Cancer Res. 2023;83(10):1684\u201398.","journal-title":"Cancer Res"},{"issue":"1","key":"1858_CR86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"key":"1858_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072528","author":"IZ Uras","year":"2020","unstructured":"Uras IZ, Sexl V, Kollmann K. CDK6 inhibition: a novel approach in AML management. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21072528.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1858_CR88","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41467-021-21204-5","volume":"12","author":"P Sachamitr","year":"2021","unstructured":"Sachamitr P, et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat Commun. 2021;12(1):979.","journal-title":"Nat Commun"},{"issue":"7","key":"1858_CR89","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"Roboz GJ, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463\u201371.","journal-title":"Blood"},{"issue":"5","key":"1858_CR90","volume":"9","author":"W Liu","year":"2014","unstructured":"Liu W, et al. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS ONE. 2014;9(5):e98270.","journal-title":"PLoS ONE"},{"issue":"14","key":"1858_CR91","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39(14):1584\u201394.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01858-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:32Z","timestamp":1764917432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01858-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1858"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01858-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"311"}}